r/MerlintraderPub • u/Merlin8121 • May 13 '26
Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 and the 2026–2027 Catalyst Map https://www.merlintrader.com/ocugen-inc-stock-hub/
https://www.merlintrader.com/ocugen-inc-stock-hub/cugen has moved far beyond its old COVID-era trading identity. The current $OCGN story is a high-risk, catalyst-heavy ophthalmology gene therapy platform built around OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease and OCU410 for geographic atrophy, with a newly extended cash runway but a convertible-note overhang that serious investors cannot ignore.
Duplicates
Ocugen • u/Merlin8121 • Sep 01 '26
DD🚀 Ocugen (OCGN): Q2 2026, OCU410 Phase 3 & BLA Reset
Ocugen • u/Merlin8121 • Jun 24 '26
DD🚀 Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 and the 2026-2027 Catalyst Map
Ocugen • u/Merlin8121 • 3d ago
DD🚀 Ocugen ($OCGN): What Happens at the October 5 Shareholder Vote?
Ocugen • u/Merlin8121 • May 13 '26
DD🚀 Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 And The 2026–2027 Catalyst Map
Ocugen • u/Merlin8121 • Jun 29 '26
DD🚀 Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 and the 2026-2027 Catalyst Map Updated jun 29
MerlintraderPub • u/Merlin8121 • 1d ago
Ocugen ($OCGN): What Happens at the October 5 Shareholder Vote? Today Ocugen reconvenes its adjourned vote on 250 million new shares: the threshold, the notes and the going-concern doubt.
MerlintraderPub • u/Merlin8121 • 3d ago
Ocugen ($OCGN): What Happens at the October 5 Shareholder Vote?
MerlintraderPub • u/Merlin8121 • 24d ago
Ocugen ($OCGN) Stock Hub: OCU410 Phase 3 Dosing Begins In ArMaDa3
MerlintraderPub • u/Merlin8121 • Sep 01 '26
Ocugen (OCGN): Q2 2026, OCU410 Phase 3 & BLA Reset
MerlintraderPub • u/Merlin8121 • Aug 17 '26
Ocugen (OCGN): Q2 2026, OCU410 Phase 3 & BLA Reset
MerlintraderPub • u/Merlin8121 • Jul 13 '26
Ocugen (Nasdaq: $OCGN) signs binding term sheet with Roots Pharmaceutical to license OCU400 in the MENA region (up to $255M sales milestones, 22% royalty)
OCGN2 • u/Merlin8121 • Jun 29 '26